Welcome to our dedicated page for Virax Biolabs Group news (Ticker: VRAX), a resource for investors and traders seeking the latest updates and insights on Virax Biolabs Group stock.
Virax Biolabs Group Ltd (VRAX) delivers cutting-edge solutions in viral disease detection through its proprietary T-Cell diagnostic technologies. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's advancements in immune profiling and diagnostic innovations.
Access authoritative information about VRAX's operational developments, including regulatory milestones, research collaborations, and product launches. Our curated collection features earnings reports, partnership announcements, and scientific breakthroughs related to Long COVID diagnostics and chronic viral infection management.
The platform serves as a comprehensive resource for tracking VRAX's progress in developing its T-Cell testing platform and expanding global distribution networks. Users will find updates on clinical validation studies, new assay developments, and strategic initiatives enhancing viral detection capabilities.
Bookmark this page for streamlined access to verified information about VRAX's contributions to immunology research and diagnostic solutions. Stay informed about critical developments through our organized repository of company announcements and industry analyses.
Virax Biolabs (NASDAQ: VRAX) has initiated patient enrollment in a UK-based, multi-center clinical study (NCT06731179) to evaluate their ViraxImmune™ FluoroSpot T cell assay. The study aims to detect T cell dysfunction in patients with post-acute infection syndromes, including:
- Long COVID
- Post-treatment Lyme disease (PTLD)
- Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)
The clinical trial, conducted in partnership with the UK's National Health Service, will enroll up to 200 participants. Initial data from this longitudinal assessment is expected in Q2 2026. The company aims to develop reliable diagnostics for these conditions, potentially enabling earlier treatment intervention and improved patient outcomes.
Virax Biolabs (Nasdaq: VRAX) presented research data on T-Cell dysfunction in post-acute infection syndromes (PAIS) at the World Immune Regulation Meeting in Davos, Switzerland. The study demonstrated that repeated stimulation of peripheral blood mononuclear cells with SARS-CoV-2 and CMV peptide pools increases the expression of exhaustion markers in CD4⁺ and CD8⁺ T-Cells.
The research showed that T-Cell exhaustion correlates with reduced cytokine production, particularly pro-inflammatory cytokines, leading to impaired immune functionality. Preliminary data from the ViraxImmune™ PAIS assay revealed significant differences in cytokine levels between PAIS patients and healthy controls.
The company has initiated clinical validation studies to evaluate their T-Cell-based diagnostic's performance in assessing the relationship between T-Cell dysfunction and symptoms like chronic fatigue and cognitive impairment in conditions such as long COVID, ME/CFS, and chronic Lyme disease.
Virax Biolabs (Nasdaq: VRAX) has announced its participation in the prestigious 19th World Immune Regulation Meeting (WIRM) taking place March 12-15, 2025, in Davos, Switzerland. The company's Chief Operating Officer, Dr. Nigel McCracken, will deliver a presentation titled 'Evaluation of T cell dysfunction in post acute infection syndromes' on March 12, 2025, at 20:00 in Foyer A1 of The Congress Center.
The biotechnology company, focused on viral disease diagnosis and immune response detection, will also showcase its immune profiling products at Booth 116. Management will be available to engage with research organizations and potential customers during the event.
WIRM 2025 is set to bring together approximately 600 scientists and clinicians worldwide, featuring scientific lectures, networking opportunities, and a poster exhibition in Davos.
Virax Biolabs Group (NASDAQ: VRAX) believes its technology aligns with the United States Department of Health and Human Services' commitment to prioritizing transparency on vaccine efficacy. This initiative is essential for empowering the public with the information needed to make informed health decisions. Virax Biolabs recognizes the essential role vaccines play in public health and is committed to ensuring vaccine efficacy. The Company asserts the importance of transparency regarding vaccine effectiveness and how individual immune profiles impact vaccination decisions, enabling informed, empowered choices about personal health.
Virax Biolabs is positioned to advance vaccine transparency in collaboration with companies developing vaccines. Our cutting-edge technology enables us to provide research-based tools to measure the efficacy of the vaccines as well as monitor long-term immune protection for individuals following vaccination. These solutions further capitalize on Virax Biolabs' innovative platform to deliver comprehensive immune profiling solutions, with a focus on advancing research in protective immunity and T cell dysfunction.
"As this new administration appears to enter a new era of vaccine transparency, we believe Virax Biolabs is well-positioned to provide additional critical, data-driven insights on vaccine efficacy to support existing and future vaccine development," said James Foster, Chief Executive Officer of Virax Biolabs. "We are fully aligned in supporting Public Health initiatives around Vaccine Efficacy Testing."
Virax Biolabs (NASDAQ: VRAX) has issued a shareholder letter outlining achievements and plans. The company launched ImmuneSelect, a research-use-only version of their ViraxImmune™ platform, and expanded distribution partnerships in Europe. A clinical study (NCT06731179) in the UK will assess ViraxImmune™'s performance in detecting T-cell dysfunction, with first patient dosing expected in Q1 2025.
Financial highlights include R&D acceleration, with lab area tripled and equipment doubled to $1.1M. The company raised approximately $5.9M through warrant exercise and stock transactions. As of September 30, 2024, cash balance was $7.3M with $6.6M working capital and no long-term debt.
2025 priorities include advancing clinical validation studies, initiating FDA interactions, expanding ImmuneSelect distribution to U.S. markets, and starting protective immunity IVD clinical performance studies.
Virax Biolabs (NASDAQ: VRAX) has signed a non-exclusive distribution agreement with French company Tebubio to distribute its ImmuneSelect Research Use portfolio across the European Union, Norway, and Switzerland. The partnership aims to increase accessibility of ImmuneSelect for life science institutions throughout Europe.
Tebubio's established distribution networks and relationships across Europe will facilitate broader access to ImmuneSelect for research purposes. The collaboration represents a strategic expansion of Virax's immune profiling technology in the European market.
Virax Biolabs (NASDAQ: VRAX) has signed a distribution agreement with Europa Biosite to commercialize its ImmuneSelect Research Use portfolio in the United Kingdom and Ireland through Cambridge Bioscience subsidiary. The partnership aims to expand Virax's commercial presence in these markets, making ImmuneSelect's immune profiling solutions accessible to researchers and pharmaceutical companies studying T cell response and immune status. Europa Biosite will provide local technical support and leverage its commercial infrastructure for product delivery.
Virax Biolabs Group (NASDAQ: VRAX) has extended its exclusive distribution agreement with Cosmos Health Inc. (Nasdaq: COSM) to market Mpox Virus Real-Time PCR Detection Kits in Gulf Cooperation Council (GCC) countries. This expansion follows their existing agreement for Greece, Cyprus, and non-exclusive distribution in Europe. The CE-marked and MHRA-authorized kits boast a 96.7% sensitivity and 93.72% specificity, delivering results in under 70 minutes.
The agreement allows Cosmos to import, sell, and distribute Virax-branded Mpox virus Nucleic Acid Detection Kits in Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates. Both companies express excitement about the partnership, with Virax CEO James Foster highlighting the expanded geographic reach and Cosmos CEO Greg Siokas noting the continued strong demand for Mpox virus detection kits.
Virax Biolabs (NASDAQ: VRAX), a biotechnology company specializing in viral disease detection and immune response diagnosis, announced its participation in H.C. Wainwright's 26th Annual Global Investment Conference in New York, NY. The company's Chief Operating Officer, Dr. Nigel McCracken, is presenting at the conference, which runs from September 9-11, 2024 at the Lotte New York Palace Hotel. A pre-recorded, on-demand presentation is now available for viewing.
Virax management is also offering one-on-one meetings during the conference for interested parties. The presentation can be accessed through the company's investor relations website.
Virax Biolabs Group (VRAX) has announced its participation in the 7th European Congress of Immunology (ECI) from September 1-4, 2024, in Dublin, Ireland. The company will showcase its immune profiling products for research use at Booth C13. Management will be available for discussions with research organizations and potential customers.
The ECI is a prestigious triennial event organized by the European Federation of Immunological Societies (EFIS), attracting over 3,000 delegates in the field of basic and clinical immunology. This year's congress theme is 'Conquering challenges with Immunology', highlighting the importance of immunological research in addressing current health challenges.
